Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Share News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.15
Bid: 2.10
Ask: 2.19
Change: 0.035 (1.66%)
Spread: 0.09 (4.286%)
Open: 2.06
High: 2.15
Low: 2.06
Prev. Close: 2.11
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: Stocks looking for direction before US inflation

Wed, 12th Apr 2023 08:49

(Alliance News) - Stock prices in London opened mixed on Wednesday, as caution prevailed ahead of a US inflation reading and minutes from the Federal Reserve's March meeting.

The FTSE 100 index opened up 20.87 points, 0.3%, at 7,806.59. The FTSE 250 was down 33.76 points, 0.2%, at 18,922.29, and the AIM All-Share was down 0.62 of a point at 816.23.

The Cboe UK 100 was 0.3% higher at 780.92, the Cboe UK 250 down 0.3% at 16,482.70, and the Cboe Small Companies was down 0.6% at 13,189.85.

In European equities, the CAC 40 in Paris and the DAX 40 in Frankfurt both were up 0.2%.

"A dose of caution has been injected into financial markets as investors brace for the latest reading on US inflation," said Hargreaves Lansdown analyst Susannah Streeter.

US inflation data for March will be released at 1330 BST. Markets are expecting the annual inflation rate to cool to 5.2% from 6.0%, according to FXStreet. From the previous month, consumer prices are expected to rise 0.4%, compared to 0.5% in February.

Core inflation - excluding food and energy - is expected to edge up to 5.6% annually from 5.5% in February.

"The worry is that core inflation...may be proving harder to bring down more quickly, which could harden [Federal Reserve] policymakers' resolve," HL's Streeter noted.

"Another 0.25% hike is already expected in May, and a stronger than expected core inflation reading, could tip the balance in forecasts towards yet another rate rise in June, which may set off a fresh round of equity selling, particularly for companies in the sensitive tech sector," she added.

There also will be the release of the Federal Open Market Committee meeting minutes at 1900 BST.

At its March meeting, the Fed lifted interest rates by 25 basis points to a 475-500 basis point target range, resisting the urge to pause hikes in the face of banking sector turmoil.

"There is likely to be reference to the recent banking turmoil, although comments from one Fed member have already suggested that there are no signs yet of business or consumer spending being influenced by tighter lending conditions," said interactive investor analyst Richard Hunter.

In the US on Tuesday, Wall Street had a muted session, with the Dow Jones Industrial Average ending up 0.3%, the S&P 500 flat, and the Nasdaq Composite down 0.4%.

The dollar was mixed against major currencies in early exchanges.

Sterling was quoted at USD1.2432 early Wednesday, higher than USD1.2427 at the London equities close on Tuesday. The euro traded at USD1.0931, up from USD1.0914. Against the yen, the dollar was quoted at JPY133.64, up slightly versus JPY133.61.

In Asia on Wednesday, the Nikkei 225 index closed up 0.6%. In China, the Shanghai Composite added 0.4%, though the Hang Seng index in Hong Kong was down 1.0%. The S&P/ASX 200 in Sydney closed up 0.5%.

In London's FTSE 100 index, student accommodation provider Unite added 0.7%, updating on its UK Student Accommodation Fund and London Student Accommodation joint venture's quarterly trading.

In the 2023/24 academic year, it noted "strong progress" in booking, with 90% of rooms already sold.

"Reservations are significantly ahead of recent sales cycles, reflecting strong demand from both new and existing students as well as new nomination agreements with universities," said Chief Executive Richard Smith.

The progress reinforces its confidence in rental growth of 6% to 7% for the academic year, Unite said.

Anglo American fell 1.6%.

The miner announced the value of rough diamond sales for De Beers in the third sales cycle of the year. Sales values rose to USD540 million from USD497 million in the second cycle. However, sales were down from USD566 million in the third cycle of 2022. The third cycle ran from March 27 to April 11.

"Sales were in line with expectations and we continue to see some encouraging positive trends in consumer demand for diamond jewellery, not least in China where we're beginning to see some signs of recovery in consumer confidence following the relaxation of travel restrictions," said De Beers CEO Al Cook.

Gold was quoted at USD2,016.14 an ounce early Wednesday, higher than USD2,002.83 on Tuesday.

In the FTSE 250, Tullow Oil dropped 4.0%, as Jefferies cut the stock to 'underperform' from 'hold'.

Brent oil fetched USD85.80 a barrel, higher than USD85.22.

Elsewhere, Hikma Pharmaceuticals fell 0.5% as it named Riad Mishlawi as its new chief executive officer.

Mishlawi will become CEO from September 1, and is currently the president of Hikma's Injectables business. Acting CEO Said Darwazah will step down, and resume his role as executive chair.

Among London's small-caps, De La Rue plunged 29%.

The banknote printer said it has been hurt by demand for banknotes sinking to a more than 20-year low. It expects full year adjusted operating profit for the year ended March 25 to be "a mid-single digit percentage below market expectations".

De La Rue said it is seeing signs of recovery, with a "significant number of new tenders actively underway", though the pace of a bounce back is uncertain.

De La Rue added: "The company is in discussions with its lending banks in relation to seeking an amendment to its banking covenants, reflecting the revised outlook and also reflecting the increase in the company's funding costs resulting from higher Bank of England base rates."

More positively, it expects revenue in its Authentication to top GBP100 million for the first time in the new financial year.

On AIM, ImmuPharma jumped 10%.

The specialist drug discovery and development company said it had received confirmation of a meeting with the US Food & Drug Administration. The pre-investigational new drug meeting will take place on May 16. It concerns the phase 2/3 adaptive trial study protocol for P140 in chronic idiopathic demyelinating polyneuropathy.

"We are delighted to be moving P140 into its second indication for CIDP patients who suffer from a rare disease with high unmet medical need. This is a great example of P140's broad potential," said CEO Tim McCarthy.

By Elizabeth Winter, Alliance News senior markets reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
28 Jan 2013 12:58

Immupharma reports success of partner's latest Lupus drug trial

Drug development firm ImmuPharma said Monday that its key scientific collaboration partner and the inventor of ImmuPharma's lead compound, Lupuzor, has confirmed the effectiveness of a product known as Lupuzor peptide P140. Partner CNRS released a statement saying that in a clinical trial involvin

Read more
27 Mar 2012 10:27

ImmuPharma's losses grow in 2011

Drug development firm ImmuPharma increased its losses during 2011 but managed to regain the rights to its most important compound. The loss for the year was £3.35m, against the prior year's loss of £1.98m. The loss per share increased from 2.44p in 2010 to 4.12p in 2011. ImmuPharma's lead product

Read more
24 Jan 2012 16:32

SABMiller exec buys a round

The Managing Director of SABMiller's African division bought a round of shares just one day before the drinks giant announced it has signed a definitive transaction agreement with Anadolu Group and Anadolu Efes. The agreement allows the firm to form a strategic alliance between the firm's divisions

Read more
5 Apr 2011 12:01

Immupharma posts wider losses

Drug discovery group Immupharma fell into losses in the year to 31 December, but pointed to progress with its ongoing trials. Pre-tax losses totalled £2m for the year, against a profit of £9.1m the previous year. Revenues fell to just £325,000 from £22.05m. "Early results of our cancer programme

Read more
23 Jun 2010 16:00

UK SMALLCAP ROUNDUP: Mariana Resources Raises GB6.75 Million

Dow Jones smallcap news is on Twitter, allowing you to catch up on the news away from your desk. Go to http://twitter.com/DJ_UK_Smallcaps MARIANA RESOURCES LTD. (MARL.LN), a gold, silver and copper explorer, Wednesday said it agreed to raise GBP6.75 million in a share sale to fund drilling at i

Read more
23 Jun 2010 07:28

Immupharma Partner Cephalon Starts Phase 2b Trials Recruitment

LONDON (Dow Jones)--Immupharma PLC (IMM.LN), a specialist drug discovery and development company, said Wednesday that Cephalon Inc. (CEPH), its license partner for IPP-201101 (Rigerimod; Lupuzor) has started the recruitment of lupus patients for a Phase IIb trial in the U.S. MAIN FACTS: -Stu

Read more
19 Nov 2009 11:01

Small caps round-up: White Young Green, Beowulf, Angel Biotech...

Engineering consultant White Young Green has traded in line with expectations since the end of June, with conditions varying across its markets. "There remains a lack of confidence and liquidity in many areas in which we trade, but there are also some encouraging signs in respect of opportunities

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.